"The Patent Trial and Appeal Board ruled that the inventions claimed in the pending U.S. patent application filed by the Doudna/Charpentier research group and the patents and applications filed by the Broad Institute are separately patentable from one another, thereby moving the Doudna/Charpentier group’s application closer to issuance as a U.S. patent."
MCB Affiliated Professor Dan Fletcher (who is Chair of the Department of Bioengineering) was one of the thirteen UC Berkeley faculty that were named Chan Zuckerberg Biohub Investigators. Fletcher "will launch a new effort to map the topography and spatial organization of cell-cell surfaces, starting with macrophages in their interactions with tumor cells."
The MCB Department is fully committed to supporting, in every way possible, all members of our department, irrespective of their national origin, religious background, race, color, age, sex, gender, gender identity, or sexual orientation. We are particularly troubled by the recent Executive Order on Immigration because it threatens members of our community and the practice of science. MCB scientists and staff come from many countries and engage in numerous international collaborations. Our research is enhanced by the diversity of perspectives provided by scientists from different backgrounds including international scientists. In addition, everyone’s science benefits when all scientists can travel freely between the U.S. and other countries to communicate directly with each other. We will resist policies that threaten our scientific culture and values.
"Jennifer Doudna and Emmanuelle Charpentier were awarded the Japan Prize today for their invention of the revolutionary gene-editing technology known as CRISPR-Cas9, which has swept into research labs around the world and is already yielding new therapies for cancer and hereditary diseases."